Browsing Tag
Takeda Pharmaceutical
25 posts
Pharma M&A trends 2026: Why $1.3tn in firepower is meeting the steepest patent cliff in industry history
Big pharma has $1.3 trillion to deploy and $230 billion in revenue going off-patent by 2030. The 2026 deal map shows where the panic is real.
Ovid Therapeutics (NASDAQ: OVID) surges 28% on $175m private placement: What does it mean for biotech investors?
Ovid Therapeutics (NASDAQ: OVID) jumped 28% after securing $175M via a PIPE deal. Explore its pipeline focus, stock sentiment, and investor outlook.
Axcelead DDP partners with Astellas for targeted protein degrader discovery
Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) has entered into a strategic service agreement with Astellas Pharma, Inc.,…
Ascentage Pharma, Takeda forge $1.3bn deal to advance leukemia treatment
Ascentage Pharma (6855 HK), a leading biopharmaceutical company, has announced a significant development in its partnership strategy by…
Torrent Pharmaceuticals licenses Vonoprazan from Takeda to treat GERD in India
Torrent Pharmaceuticals Limited has secured a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company Limited to commercialize Vonoprazan,…
Takeda’s TAK-279 meets primary endpoint in Phase 2b trial for psoriatic arthritis
Takeda Pharmaceutical Company announced positive results from its Phase 2b clinical trial for TAK-279, an investigational oral TYK2…
Takeda’s TAK-755 shows potential in Phase 3 trial for cTTP prophylaxis
Takeda Pharmaceutical Company has revealed promising interim results from its global Phase 3 trial of TAK-755, a recombinant…
Takeda’s HYQVIA reduces CIDP relapse rates, Phase 3 trial reveals
Takeda Pharmaceutical Company has disclosed successful outcomes from its critical Phase 3 ADVANCE-CIDP 1 trial, focused on evaluating…
Takeda signs licensing deal for Hutchmed’s fruquintinib outside of China
Takeda Pharmaceutical will acquire an exclusive worldwide license, excluding China, of fruquintinib from Hutchmed (China) and its subsidiary…
Takeda gets QDENGA EC approval as dengue vaccine
Takeda has received the European Commission’s (EC) marketing authorization for the company’s dengue vaccine QDENGA (Dengue Tetravalent Vaccine…